CARY, N.C., June 11, 2025 /PRNewswire/ -- WCG, a global leader in providing solutions that measurably improve and accelerate clinical research, proudly announces the winners of the first-ever prestigious WCG Pinnacle Award, Site Relationships. Award winners were chosen based on the results of WCG's 2025 CenterWatch Global Site Relationship Survey that captured insights from more than 12,000 respondents, including more than 19,000 ratings for sponsors and nearly 10,000 ratings for CROs, highlighting 40 key attributes such as communication quality, professionalism, technology use, and efficient site management.Designed to honor exemplary performance in fostering strong relationships between clinical trial sponsors or contract research organizations (CROs) and investigational sites, this accolade emphasizes the dedication to enhancing collaboration, protocol excellence, site operations, participant diversity, and technology management required to advance clinical research for the betterment of medical science and patient care. WCG Pinnacle Award recipients represent the top performers based upon customer satisfaction (CSAT) scores across a variety of attributes.2025 WCG Pinnacle Award, Site Relationship winners include:Bayer – Overall Site Relationship LeaderNovo Nordisk – Overall Site Relationship LeaderIQVIA – Leadership in Professionalism and CommunicationMedpace – Leadership in Professionalism and CommunicationParexel – Leadership in TechnologyThe 2025 award winners have demonstrated exceptional commitment to advancing clinical research through strong site relationships, reinforcing their status as industry leaders and role models."We are honored to recognize organizations like Bayer, Novo Nordisk, IQVIA, Medpace, and Parexel that excel in the vital area of site relationships," said Sam Srivastava, chief executive officer, WCG. "Pinnacle Award recipients exemplify the industry's drive toward innovation and excellence, enhancing clinical trial collaborations. Their dedication inspires continued progress in clinical research throughout the industry.""Strong site relationships are essential for the successful navigation of clinical trials," noted Mette Andersen, general manager, Data & Insights, WCG. "These award-winning organizations have shown that fostering site connections leads to more efficient operations and improved outcomes in clinical research."Since 1997, the WCG CenterWatch Global Site Relationship Survey has served as a valuable tool for sponsors and CROs seeking to benchmark their practices and drive improvements

Acquisition of WCG's electronic clinical outcome assessments (eCOA) business will expand Clario's scientific expertise and offerings in neurosciencePHILADELPHIA, March 10, 2025 /PRNewswire/ -- Clario, a leading provider of endpoint data solutions to the clinical trial industry, today announced they have entered into a definitive agreement to acquire the eCOA business of WCG, a leader in providing solutions that measurably improve and accelerate clinical research. Electronic clinical outcomes assessments (eCOA), in addition to paper assessments, are used to evaluate the safety and efficacy of new drugs by measuring how a clinical trial participant feels or functions. WCG's eCOA operations offer robust, full-service clinical expertise and specialized functionality, particularly in neurology, psychiatry, neuropathic pain, and rare diseases

CARY, NORTH CAROLINA / ACCESS Newswire / January 30, 2025 / Yunu, a leading provider of clinical trial imaging workflow and data management solutions, is pleased to announce its partnership with WCG, a global leader in clinical trial solutions, in support of WCG's imaging services. WCG is one of the world's largest clinical services organizations, providing solutions that directly impacted 93% of all FDA-approved therapeutics last year.Yunu manages more than 5,000 active clinical trial protocols and serves as the primary source of imaging endpoint data for over 25% of all NCI-designated cancer centers. The partnership between Yunu and WCG enables the companies to revolutionize their capabilities in trial imaging, providing sponsors and sites with enhanced support to ensure accurate, efficient, and transparent clinical trials.With Yunu's advanced platform, WCG has expanded its ability to support critical imaging workflows for trial sponsors, offering real-time transparency to highly accurate trial imaging data. The platform provides support for WCG imaging services, eliminating ineffective and redundant systems, streamlining imaging services, further decreasing start-up timelines, and creating a robust foundation for managing larger, more complex prospective trial workflows while also accelerating their growing portfolio of imaging AI validation trials.Through this collaboration, Yunu empowers WCG to provide a differentiated experience for sponsors, where they can:See Everything : Access live insights and analytics for greater control over trial progress.Collaborate Freely : Communicate with all trial stakeholders through a common platform.Move Faster: Streamline processes and minimize inefficiencies to deliver expedited, more effective trials.WCG now also offers Yunu capabilities to trial sites, harmonizing workflow and supplying critical imaging assessment tools that ensure compliance with each trial's specific protocol. Leveraging Yunu to deliver imaging accuracy at the source eliminates downstream delays and site-central discordance. Cancer centers are already rapidly adopting the Yunu platform for imaging across all trials to improve trial imaging accuracy, patient qualification and retention, and to gain insights from earlier tumor response signals.This collaboration underscores Yunu's and WCG's commitment to better serve sponsors, sites, and ultimately, clinical trial participants